Clinical Trials in Brazil / NCT07093112
Active, not recruiting Not applicable

Decoding Gut-Brain Biomarkers and Developing a Minimally Intrusive Gut Microbiome Sampling: Enhancing Cognitive Well-being in Athletes

NCT07093112 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2025-03-10
Last updated
2025-07-30

Condition(s) studied

Athletic PerformanceGut Health

Investigational drug(s) / intervention(s)

Psychobiotic supplementPlacebo

Psychobiotic supplement: The psychobiotic supplement consists of Bifidobacterium lactis CCT 7858 and Lactobacillus rhamnosus CCT 7863, at a final concentration of 1 x 10\^10 CFU/g (GABBIA® Biotechnology, Santa Catarina, Brazil). The intervention will be administered once daily for 90 days, spanning the pre-season and start-season phases with an interval and restarting for 90 days until the end-season phase.

Placebo: The placebo consists of maltodextrin. The intervention will be administered once daily for 90 days, spanning the pre-season and start-season phases with an interval and restarting for 90 days until the end-season phase.

Study summary

The objective of this study is to assess the impact of a psychobiotic supplement on the gut health, neurological markers, and behavior of younger soccer players over the soccer season.

Eligibility

Sex
ALL
Min age
14 Years
Max age
25 Years
Healthy volunteers
Accepted
Inclusion Criteria: * soccer player affiliated with Criciúma Esporte Clube (CEC)'s base in Criciúma, Santa Catarina, Brazil * agree to participate voluntarily Exclusion Criteria: * athletes who withdraw from the study, cannot collect biological samples or answer the questionnaires during the pre-established times, and fail to take the capsules recommended in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Universidade do Extremo Sul Catarinense (UNESC) Criciúma Santa Catarina

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07093112 on ClinicalTrials.gov ↗ ← All trials in Brazil